Development of a new hydrogel for the prevention of allergic contact dermatitis

Int J Pharm. 2022 Nov 25:628:122265. doi: 10.1016/j.ijpharm.2022.122265. Epub 2022 Oct 8.

Abstract

Allergic contact dermatitis (ACD) is the most prevalent occupational disease and the most common form of immunotoxicity in humans. Preventing exposure to the triggering allergens is the mainstay of treatment. However, avoidance is not always possible in an occupational setting. From a pathophysiological point of view, a variety of events are involved in the development of ACD, including the formation of immunogenic complexes following the stable association of the allergen with skin proteins, which is thought to be the molecular initiating event responsible for the development of ACD. Previously, the team identified molecules that exhibited higher antiallergic potential due to their capacity to block the interaction between allergens and skin proteins. These assumptions were the starting point for the design of this work aiming to develop and characterize a new hydrogel containing the active ingredients lysine and N-acetyl cysteine under the premises of quality- and safety- by design. Two factorial plannings were established envisioning the optimization of the hydrogel in terms of mechanical and rheological properties. In vitro release and permeation studies supported its skin surface barrier effect. In addition, the selected hydrogel proved to be safe without causing human skin irritation or skin sensitization.

Keywords: 1-Fluoro-2,4-dinitrobenzene; 2-Methyl-1,2-thiazol-3(2H)-one; Allergic contact dermatitis; Hydrogel; Maturation; Permeation; Prevention; Quality by design; Skin barrier.

MeSH terms

  • Allergens
  • Dermatitis, Allergic Contact* / prevention & control
  • Humans
  • Hydrogels*
  • Skin

Substances

  • Hydrogels
  • Allergens